Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-02-20 @ 6:40 PM
Study NCT ID:
NCT01987167
Status:
COMPLETED
Last Update Posted:
2017-08-22
First Post:
2013-11-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
Sponsor:
Neuro-Ophthalmologic Associates, PC
Organization:
Study Overview
Official Title:
Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACHTAR
Brief Summary:
The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.
Detailed Description:
Determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| ACTHAR | OTHER | Questcor Pharmaceuticals, Inc. | View |